Drugs / T-DXd
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT05765851 Background | May 2023 → May 2030 expected | neoplasm | Daiichi Sankyo | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | T-DXd | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05765851 ↗ |
| Route | Intravenous | “One IV infusion Q3W on Day 1 of each 21-day cycle” NCT05765851 ↗ |